NASDAQ:CDXS Codexis - CDXS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.94 -0.16 (-3.90%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.91▼$4.1950-Day Range$3.81▼$6.7652-Week Range$3.79▼$22.22Volume512,368 shsAverage Volume634,149 shsMarket Capitalization$259.83 millionP/E RatioN/ADividend YieldN/APrice Target$18.83 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Codexis MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside378.0% Upside$18.83 Price TargetShort InterestBearish7.69% of Float Sold ShortDividend StrengthN/ASustainability-3.67Upright™ Environmental ScoreNews Sentiment0.95Based on 3 Articles This WeekInsider TradingSelling Shares$716,599 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.89) to ($0.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector373rd out of 1,009 stocksIndustrial Organic Chemicals Industry11th out of 20 stocks 3.5 Analyst's Opinion Consensus RatingCodexis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.83, Codexis has a forecasted upside of 378.0% from its current price of $3.94.Amount of Analyst CoverageCodexis has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.69% of the float of Codexis has been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Codexis has recently decreased by 1.61%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Previous Next 2.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCodexis has received a 14.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Industrial enzymes for pharmaceuticals", "Biochemical assay kits", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Codexis is -3.67. Previous Next 3.3 News and Social Media Coverage News SentimentCodexis has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Codexis this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat Follows3 people have added Codexis to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $716,599.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Codexis is held by insiders.Percentage Held by Institutions93.41% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Codexis are expected to grow in the coming year, from ($0.89) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -7.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -7.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Codexis (NASDAQ:CDXS) StockCodexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.Read More Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXS Stock News HeadlinesMarch 27, 2023 | finance.yahoo.comCodexis, Inc.'s (NASDAQ:CDXS) Intrinsic Value Is Potentially 24% Below Its Share PriceMarch 20, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Codexis (NASDAQ:CDXS)March 30, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.February 27, 2023 | finance.yahoo.comCodexis to Participate in Cowen 43rd Annual Health Care ConferenceFebruary 27, 2023 | finance.yahoo.comThese Analysts Think Codexis, Inc.'s (NASDAQ:CDXS) Sales Are Under ThreatFebruary 24, 2023 | finance.yahoo.comQ4 2022 Codexis Inc Earnings CallFebruary 15, 2023 | finance.yahoo.comCodexis Announces New Employment Inducement GrantsFebruary 9, 2023 | finance.yahoo.comCodexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23March 30, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.February 7, 2023 | finance.yahoo.com15 Worst Stock Picks of Cathie Wood in 2022January 30, 2023 | finance.yahoo.comCodexis (NASDAQ:CDXS) shareholders have endured a 68% loss from investing in the stock a year agoJanuary 14, 2023 | reuters.comCDXS.P - | Stock Price & Latest News | ReutersDecember 20, 2022 | finance.yahoo.comCodexis Announces Appointment of H. Stewart Parker to Board of DirectorsDecember 20, 2022 | finance.yahoo.comHere's Why We're Not At All Concerned With Codexis' (NASDAQ:CDXS) Cash Burn SituationNovember 30, 2022 | finance.yahoo.comCodexis Shelves Development Of Certain Internal Programs, Cuts WorkforceNovember 16, 2022 | finance.yahoo.comCodexis to Participate in Piper Sandler 34th Annual Healthcare ConferenceNovember 9, 2022 | finance.yahoo.comCodexis Third Quarter 2022 Earnings: Beats ExpectationsNovember 7, 2022 | finance.yahoo.comHow Much Upside is Left in Codexis (CDXS)? Wall Street Analysts Think 219%November 2, 2022 | finance.yahoo.comWhen Should You Buy Codexis, Inc. (NASDAQ:CDXS)?November 1, 2022 | finance.yahoo.comCodexis Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General CounselOctober 27, 2022 | reuters.comCDXS.OQ - Codexis, Inc. | Stock Price & Latest News | ReutersOctober 25, 2022 | nasdaq.comCodexis, Inc. (NASDAQ:CDXS) Shares Could Be 47% Below Their Intrinsic Value EstimateOctober 11, 2022 | benzinga.comSynthetic Biology Global Market Report 2022: Synthetic Genes Open up a New World of Drug Development - BenzingaOctober 4, 2022 | finance.yahoo.comFabry Disease Market to Boost at a CAGR of 7.65% by 2032 | DelveInsight - Yahoo FinanceOctober 4, 2022 | finance.yahoo.comCodexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors - Yahoo FinanceOctober 3, 2022 | globenewswire.comCodexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors - GlobeNewswireOctober 3, 2022 | finance.yahoo.comCodexis Announces Appointment of Kevin Norrett as Chief Operating OfficerSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXS Company Calendar Last Earnings2/23/2023Today3/30/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Industrial organic chemicals Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CDXS CUSIP19200510 CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees261Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.83 High Stock Price Forecast$23.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+380.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,590,000.00 Net Margins-24.24% Pretax Margin-24.04% Return on Equity-21.78% Return on Assets-14.06% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.28 Sales & Book Value Annual Sales$138.59 million Price / Sales1.87 Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / Book1.78Miscellaneous Outstanding Shares65,947,000Free Float61,331,000Market Cap$258.51 million OptionableOptionable Beta1.64 Key ExecutivesStephen George DillyPresident, CEO & Independent DirectorKarl A. SchoeneSenior Vice President-Development & OperationsKevin NorrettChief Operating OfficerSriram RyaliChief Financial & Accounting OfficerStefan LutzSenior Vice President-ResearchKey Competitorsbluebird bioNASDAQ:BLUEAtea PharmaceuticalsNASDAQ:AVIROutlook TherapeuticsNASDAQ:OTLKPepGenNASDAQ:PEPGCue HealthNASDAQ:HLTHView All CompetitorsInsiders & InstitutionsJohn J NicolsSold 35,714 sharesTotal: $146,070.26 ($4.09/share)Stephen George DillySold 28,088 sharesTotal: $129,204.80 ($4.60/share)Kevin NorrettSold 8,596 sharesTotal: $39,541.60 ($4.60/share)John J NicolsSold 35,714 sharesTotal: $172,498.62 ($4.83/share)Alliancebernstein L.P.Bought 14,700 shares on 2/16/2023Ownership: 0.116%View All Insider TransactionsView All Institutional Transactions CDXS Stock - Frequently Asked Questions Should I buy or sell Codexis stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CDXS shares. View CDXS analyst ratings or view top-rated stocks. What is Codexis' stock price forecast for 2023? 3 analysts have issued 12 month target prices for Codexis' stock. Their CDXS share price forecasts range from $9.00 to $23.00. On average, they anticipate the company's stock price to reach $18.83 in the next twelve months. This suggests a possible upside of 376.8% from the stock's current price. View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts. How have CDXS shares performed in 2023? Codexis' stock was trading at $4.66 at the beginning of the year. Since then, CDXS stock has decreased by 15.2% and is now trading at $3.95. View the best growth stocks for 2023 here. When is Codexis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our CDXS earnings forecast. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) released its earnings results on Thursday, February, 23rd. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.04. The biotechnology company earned $30.40 million during the quarter, compared to analyst estimates of $28.92 million. Codexis had a negative net margin of 24.24% and a negative trailing twelve-month return on equity of 21.78%. The business's quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.16) EPS. What ETFs hold Codexis' stock? ETFs with the largest weight of Codexis (NASDAQ:CDXS) stock in their portfolio include Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Genomic Revolution ETF (ARKG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), WisdomTree BioRevolution Fund (WDNA) and iShares Biotechnology ETF (IBB). What guidance has Codexis issued on next quarter's earnings? Codexis updated its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63.00 million-$68.00 million, compared to the consensus revenue estimate of $91.98 million. What is John J. Nicols' approval rating as Codexis' CEO? 25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS). What is Codexis' stock symbol? Codexis trades on the NASDAQ under the ticker symbol "CDXS." Who are Codexis' major shareholders? Codexis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (9.42%), Nantahala Capital Management LLC (6.83%), ARK Investment Management LLC (6.00%), Telemark Asset Management LLC (3.96%), Geode Capital Management LLC (1.81%) and Sumitomo Mitsui Trust Holdings Inc. (1.66%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Kevin Norrett, Patrick Y Yang, Stephen George Dilly and Thomas R Baruch. View institutional ownership trends. How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Codexis' stock price today? One share of CDXS stock can currently be purchased for approximately $3.95. How much money does Codexis make? Codexis (NASDAQ:CDXS) has a market capitalization of $260.49 million and generates $138.59 million in revenue each year. The biotechnology company earns $-33,590,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. How many employees does Codexis have? The company employs 261 workers across the globe. How can I contact Codexis? Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102. This page (NASDAQ:CDXS) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.